RecruitingPlaque Psoriasis
A Phase 3 Clinical Study of QL2106 Injection
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis. A total of 318 subjects are planned to be included and randomized at a ratio of 1:1 to receive QL2106 injection orTremfya®
Sponsor: Qilu Pharmaceutical Co., Ltd.
You may qualify if…
- ✓ Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
- ✓ Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
- ✓ Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
- ✓ Total investigator global assessment (IGA) \>=3 at screening and baseline
- ✓ Candidate for phototherapy or systemic treatment for plaque psoriasis
You may not qualify if…
- ✕ Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular)
- ✕ Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
Source: ClinicalTrials.gov · NCT07511647 · last updated 2026-06-05